Recently, the Shanghai FTZ Fund has invested in PhaBuilder, a leading domestic PHA (Polyhydroxyalkanoates) company.

The latest round of financing for PhaBuilder was jointly done by Shanghai FTZ Fund and many renowned funds such as CNPC Kunlun Capital. In the future, PhaBuilder will further enhance its R&D capabilities of its Synthetic Biology Innovation Center, promote the construction of the 10,000-ton PHA production line, and accelerate the development of "PHA Life" green and low-carbon lifestyle products and its global business layout.

PhaBuilder is a company with leading synthetic biotechnology, focusing on the transformation and engineering of halophilic microorganisms. The company was founded in February 2021 by Professor Guoqiang Chen, director of the Center for Synthesis and Systems Biology at Tsinghua University. It mainly uses the cutting-edge "Next Generation Industrial Biotechnology(NGIB)" to develop and produce a variety of high-value-added products such as PHA - a biodegradable material, ectoine - a pharmaceutical intermediate, and cadaverine - a Nylon 56 precursor. 

The company currently has two PHA plants under construction - the synthetic biology intelligent development plant in Beijing China-German Industrial Park and the 10 kt/annum plant in Yichang, Hubei Province. It also plans to build up 3-5 large-scale production bases throughout China within five years. At present, PhaBuilder has completed two rounds of financing, raising around 300 million yuan in total. The investors include Sequoia Capital, China State-owned Enterprise Mixed Ownership Reform Fund, and GRC SinoGreen Fund, etc. 

In the future, PhaBuilder will constantly promote synthetic biotechnology to deeply integrate with people's lives and upgrade the intelligent biological manufacturing industry, in order to achieve its core mission of "Using microbes to change the world and build a green future".